Log In Get Started
Press Releases April 2, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Issues Stock Options as Inducements for New Employees Under NASDAQ Rule

By Marcus Reed SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SNDX

Syndax Pharmaceuticals granted inducement stock options for 228,500 shares to eight new employees as part of its 2023 Inducement Plan. These options vest over four years and are aimed at attracting and retaining talent to support its cancer therapy pipeline and ongoing clinical trials.

Key Points

  • Syndax awarded inducement grants of up to 228,500 shares to new hires to incentivize and retain employees.
  • The company's pipeline includes FDA-approved cancer therapies Revuforj® and Niktimvo™.
  • The stock options vest over four years, aligning employee interests with long-term company performance.

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1, 2026, the Company granted inducement awards to purchase up to 228,500 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre 
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com
Tel 781.684.9827


Risks

  • Vesting of stock options depends on continued employment, introducing retention risk if key employees leave.
  • Market acceptance and commercial success of the company's cancer therapies remain uncertain, impacting long-term growth.
  • Clinical trials and development risks may affect the future valuation and operational performance of the company.

More from Press Releases

Jena Acquisition Corporation II Announces Non-Compliance with Section 802.01B of the NYSE Listed Company Manual which Requires the Company to Maintain a Minimum of 300 Public Stockholders Apr 3, 2026 Midland States Bancorp, Inc. To Announce First Quarter 2026 Financial Results On Thursday, April 23 Apr 3, 2026 Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 3, 2026 Multi-Sensor Data Labeling and AI Data Operations: What Enterprise AV Teams Apr 3, 2026 Wix Announces Final Results of Modified Dutch Auction Tender Offer Apr 3, 2026